London, United Kingdom (CU)_ The National Institutes of Health (NIH) has given a $314,411 Small Business Innovation Research (SBIR) Phase I grant to Felix Biotechnology to create a microfluidics platform for fast, high-throughput screening of therapeutic bacteriophages that target disease-causing bacteria.
Bacteriophage, or phage, are bacteria’s natural predators and have an immense capacity for treating bacterial illnesses. However, the majority of phages only destroy…
